Clinician's Roundtable

Guest: Sayna Norouzi, MD


Because patients with IgA nephropathy (IgAN) often have few symptoms early in the disease course, communicating the importance of treatment and its impacts on long-term outcomes can be challenging. Join Dr. Sayna Norouzi as she discusses practical communication techniques for explaining prognosis, setting expectations around therapy, and partnering with patients to support informed treatment decisions and long-term kidney health. Dr. Norouzi is an Associate Professor of Medicine and Clinical Nephrologist at Loma Linda University Medical Center in California. She's also the Founder and Director of the Glomerular Diseases Clinic at Loma Linda and Director of the GlomCon Glomerular Diseases Fellowship Program.

Guest: Anjay Rastogi, MD, PhD


Managing IgA nephropathy (IgAN) is becoming increasingly complex. In this episode, Dr. Anjay Rastogi explains why an expert opinion—not simply a second opinion—can help clinicians confirm diagnoses, optimize treatment decisions, and connect appropriate patients with specialized care and emerging therapeutic opportunities. Dr. Rastogi is a Professor of Medicine and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA. He's also the Director of the UCLA CORE Kidney Health Program.

Guest: Anjay Rastogi, MD, PhD


Closer collaboration between nephrologists and pathologists is essential for optimizing the diagnosis and management of IgA nephropathy (IgAN). Hear from Dr. Anjay Rastogi as he highlights how pathology insights, clinical context, and ongoing communication can improve interpretation of kidney biopsy findings and support more informed treatment decisions. He's a Professor of Medicine and Clinical Chief of Nephrology at the David Geffen School of Medicine at UCLA, as well as the Director of the UCLA CORE Kidney Health Program.

Host: Alexandria May, PharmD, BCPS

Guest: David E. Griffith, MD


Even as our understanding of nontuberculous mycobacterial (NTM) lung disease advances, major gaps remain, from defining meaningful treatment success to overcoming innate drug resistance. In this conversation with Dr. Alexandria May, Dr. David Griffith shares his perspective on how recent evidence is shaping treatment decisions for these patients and explains why significant unmet needs persist. Dr. Griffith is a Professor of Medicine in the Division of Mycobacterial and Respiratory Infections within the Department of Medicine at National Jewish Health in Denver.

Host: Brian P. McDonough, MD, FAAFP

Guest: Doreen Addrizzo-Harris, MD


The biggest challenge in diagnosing nontuberculous mycobacterial (NTM) lung disease isn't confirmation; it's thinking to look for NTM in the first place. In this conversation with Dr. Brian McDonough, Dr. Doreen Addrizzo-Harris examines the subtle clinical and radiographic features that can help identify NTM earlier, discusses best practices for obtaining diagnostic cultures, and reviews how guideline-based criteria can help distinguish active disease from colonization. Dr. Addrizzo-Harris is the Fiona and Stanley Druckenmiller Professor of Pulmonary, Critical Care, and Sleep Medicine at NYU Grossman School of Medicine, as well as the Director of the Bronchiectasis and NTM Program at NYU Langone Health.